es5b05003_si_001.xlsx (2.01 MB)
Genomic, Proteomic, and Metabolite Characterization of Gemfibrozil-Degrading Organism Bacillus sp. GeD10
dataset
posted on 2016-01-19, 00:00 authored by Henrik Kjeldal, Nicolette
A. Zhou, Dirk K. Wissenbach, Martin von Bergen, Heidi L. Gough, Jeppe L. NielsenGemfibrozil is a widely used hypolipidemic
and triglyceride lowering
drug. Excess of the drug is excreted and discharged into the environment
primarily via wastewater treatment plant effluents. Bacillus sp. GeD10, a gemfibrozil-degrader, was previously isolated from
activated sludge. It is the first identified bacterium capable of
degrading gemfibrozil. Gemfibrozil degradation by Bacillus sp. GeD10 was here studied through genome sequencing, quantitative
proteomics and metabolite analysis. From the bacterial proteome of Bacillus sp. GeD10 1974 proteins were quantified, of which
284 proteins were found to be overabundant by more than 2-fold (FDR
corrected p-value ≤0.032, fold change (log2) ≥ 1) in response to gemfibrozil exposure. Metabolomic
analysis identified two hydroxylated intermediates as well as a glucuronidated
hydroxyl-metabolite of gemfibrozil. Overall, gemfibrozil exposure
in Bacillus sp. GeD10 increased the abundance of
several enzymes potentially involved in gemfibrozil degradation as
well as resulted in the production of several gemfibrozil metabolites.
The potential catabolic pathway/modification included ring-hydroxylation
preparing the substrate for subsequent ring cleavage by a meta-cleaving
enzyme. The identified genes may allow for monitoring of potential
gemfibrozil-degrading organisms in situ and increase the understanding
of microbial processing of trace level contaminants. This study represents
the first omics study on a gemfibrozil-degrading bacterium.